Piol, Diana https://orcid.org/0000-0002-8089-0490
Khalil, Bilal https://orcid.org/0000-0001-7251-4340
Robberechts, Tessa
Killian, Theo
Georgopoulou, Maria
Partel, Gabriele https://orcid.org/0000-0002-4482-3119
Wouters, David https://orcid.org/0000-0002-8000-8023
Hecker, Nikolai
Tziortzouda, Paraskevi
Verresen, Yana
Corthout, Nikky https://orcid.org/0000-0003-1176-7277
Kint, Sam https://orcid.org/0000-0002-6719-2903
Vandereyken, Katy https://orcid.org/0000-0002-4477-5866
Van Damme, Philip https://orcid.org/0000-0002-4010-2357
Voet, Thierry https://orcid.org/0000-0003-1204-9963
Davie, Kristofer https://orcid.org/0000-0003-2182-1249
Poovathingal, Suresh
Van Den Bosch, Ludo
Aerts, Stein https://orcid.org/0000-0002-8006-0315
Sifrim, Alejandro
Da Cruz, Sandrine https://orcid.org/0000-0003-1986-4565
Funding for this research was provided by:
Muscular Dystrophy Association (962700)
Muscular Dystrophy Association (1060285)
Article History
Received: 22 July 2024
Accepted: 19 September 2025
First Online: 22 December 2025
Competing interests
: L.V.D.B. is head of the Scientific Advisory Board of Augustine Therapeutics and is part of the Investment Advisory Board of Droia Ventures. The other authors declare no competing interests.